antalarmin has been researched along with clozapine in 1 studies
Studies (antalarmin) | Trials (antalarmin) | Recent Studies (post-2010) (antalarmin) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
---|---|---|---|---|---|
181 | 0 | 76 | 9,691 | 747 | 3,148 |
Protein | Taxonomy | antalarmin (IC50) | clozapine (IC50) |
---|---|---|---|
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
D | Rattus norvegicus (Norway rat) | 1.066 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
D | Bos taurus (cattle) | 4.09 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aebischer, B; Akboga, MK; Akdamar, G; Alcalay, RN; Álvarez-Pérez, S; Aydogdu, S; Balci, KG; Barcaro, G; Bišová, K; Blanco, JL; Brewer, SH; Caruthers, SD; Ceylan, O; Chadwick, JA; Chang, DD; Che, JM; Chen, QQ; Chen, W; Chen, Z; Chung, M; Chung, W; Colecraft, HM; Coteli, E; Dogan, H; Dong, S; Elsig, S; Fahn, S; Fang, XJ; Feng, MG; Fenlon, EE; Floyd, KT; Fokdal, L; Ford, B; Fortunelli, A; Freudenberg, R; Gan-Or, Z; García, ME; Gillham, C; Giovannelli, D; Goertz, RS; Gulati, V; Haie-Meder, C; Hao, YY; Hatano, K; Hines, KJ; Hines, SM; Hirakawa, H; Hoskin, P; Hu, JH; Huang, P; Huang, Y; Hubicka, U; Inoue, Y; Ishii, N; Janssen, PM; Jin, Z; Johnson, A; Jürgenliemk-Schultz, I; Kaineder, K; Kamei, K; Kang, U; Karatas, F; Kash, TL; Katayama, Y; Keupp, J; Kirisits, C; Kisacik, H; Kodama, K; Kotzerke, J; Kryczyk, A; Kuhness, D; Kuo, S; Lanza, GM; Le Bris, N; Levin, DE; Levy, OA; Li, B; Li, H; Li, X; Liang, GD; Liang, Y; Liao, RQ; Lin, JT; Lindegaard, JC; Liong, C; Liu, B; Liu, C; Liu, GH; Liu, L; Liu, Q; Liu, X; Lowe, J; Lowery-Gionta, EG; Ma, YH; Maden, O; Mankad, V; Marder, KS; Marshall, SA; Martínez-Nevado, E; Maucksch, U; Mazeron, R; Mazzone, CM; Mazzoni, P; Mezricky, D; Mizokami, Y; Naumann, A; Navarro, M; Netzer, FP; Neurath, MF; Nie, Q; Oliva, P; Ozeke, O; Peláez, T; Pfeifer, L; Pleil, KE; Pomp, S; Pötter, R; Puckerin, AA; Rafael-Fortney, JA; Raman, SV; Rastogi, N; Řezanka, M; Řezanka, T; Rinker, JA; Rouleau, GA; Runge, R; Sahin, MD; Sakai, A; Schmieder, AH; Schmitz, AJ; Schultz, EJ; Šegedin, B; Sementa, L; Shen, Y; Shiotsuki, I; Shirahama, M; Staley, J; Starovoytov, V; Sterrer, M; Strobel, D; Sturdza, A; Subramanyam, P; Surnev, S; Swager, SA; Taeymans, J; Tan, H; Tan, LT; Tanderup, K; Temizhan, A; Terao, T; Thiele, TE; Tran, T; Tucker, MJ; Vetriani, C; Vítová, M; Wang, JP; Wang, L; Wang, M; Wang, X; Waters, CH; Weng, SX; Wickline, SA; Wildner, D; Wodarcyk, AJ; Wolf, P; Wu, L; Wu, YL; Wunderlich, G; Xiong, L; Xu, P; Yang, GS; Yang, XN; Yang, Y; Yayla, C; Ying, SH; Zachleder, V; Zhang, XG; Zhang, XK; Zhang, Y; Zheng, JY; Zhong, WZ; Zhu, J; Zhu, YJ; Żmudzki, P | 1 |
1 review(s) available for antalarmin and clozapine